Agios Pharmaceuticals (NASDAQ: AGIO) boosts 2023 stock plan by 2M shares
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Agios Pharmaceuticals, Inc. reported that stockholders approved an amendment to its 2023 Stock Incentive Plan at the 2026 annual meeting. The amendment increases the number of shares of common stock available for issuance under the plan by 2,000,000 shares and raises the limit for incentive stock options by the same amount.
Stockholders also elected directors, including Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith, and approved additional proposals, with support levels reflected in detailed vote tallies such as 48,511,213 votes for one item versus 116,938 against and 15,376 abstaining.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Plan share increase: 2,000,000 shares
Incentive option limit increase: 2,000,000 shares
Votes for Brian Goff: 45,757,238 votes
+3 more
6 metrics
Plan share increase
2,000,000 shares
Additional common shares available under 2023 Stock Incentive Plan
Incentive option limit increase
2,000,000 shares
Extra shares that may be issued as incentive stock options
Votes for Brian Goff
45,757,238 votes
Director election at 2026 annual meeting
Votes for key proposal
43,396,045 votes
Votes for the proposal with 1,086,059 against and 1,606,976 abstaining
High-support proposal
48,511,213 votes for
Proposal with 116,938 against and 15,376 abstaining, no broker non-votes
Broker non-votes (several items)
2,554,446
Broker non-votes on multiple meeting proposals
Key Terms
2023 Stock Incentive Plan, incentive stock options, definitive proxy statement, broker non-votes, +1 more
5 terms
2023 Stock Incentive Plan financial
"the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan (the “Current Plan”)."
incentive stock options financial
"and increases the number of shares of common stock of the Company that may be issued as incentive stock options"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
definitive proxy statement regulatory
"Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
broker non-votes financial
"Votes For | | Votes Withheld | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Exhibit 99.1 regulatory
"99.1 | | Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, as amended"
Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.
FAQ
What did Agios Pharmaceuticals (AGIO) stockholders approve at the 2026 annual meeting?
Stockholders approved an amendment to the 2023 Stock Incentive Plan. The change increases available common shares under the plan by 2,000,000 and raises the cap on incentive stock options by the same amount, supporting the company’s ability to grant future equity awards.
Which Agios (AGIO) directors were elected at the 2026 annual meeting?
Stockholders elected Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith. For example, Brian Goff received 45,757,238 votes for and 331,843 votes withheld, with 2,554,446 broker non-votes, indicating broad support for the company’s leadership slate.
Where can investors find the full text of Agios’s amended 2023 Stock Incentive Plan?
The complete 2023 Stock Incentive Plan, as amended, is filed as Exhibit 99.1. It is incorporated by reference from Appendix A to Agios’s definitive proxy statement on Schedule 14A filed with the SEC on April 24, 2026.
What document describes Agios’s 2023 Stock Incentive Plan in more detail?
A detailed description of the 2023 Stock Incentive Plan, as amended, appears on pages 90 to 103 of Agios’s definitive proxy statement for the 2026 annual meeting, filed with the SEC on April 24, 2026 and incorporated by reference.